For more than three decades, generic drugmakers competed on a simple formula: enter fast, manufacture at scale and cut costs. Generics and biosimilars saved the U.S. healthcare system $496 billion in 2025, according to the Association for Accessible Medicines’ 2026 savings report. That formula is now under strain. Purchasers have consolidated, prices face pressure, much…
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
In the U.S. market, generics play a significant role in reducing overall drug spending. The FDA, for instance, estimated that the generics it approved in 2022 alone saved $18.9 billion in their first year on the market. Those savings come out of margins that keep thinning, because generic retail prices are in sustained deflation, as Brookings…

